Finally, we demonstrated that genetic targeting of specific LRRK2 substrates reduces colitis severity in Lrrk2N2081D mutation carriers, whereas a small molecule LRRK2 inhibitor did not produce a clear therapeutic effect. This evidence concerns the gene LRRK2 and colitis.